NCI/CIRB E4512 A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer - Lung
John McCann, MD
Damour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib, after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. This research study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein